Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
Authors
Keywords
-
Journal
CLINICAL INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2023-07-19
DOI
10.1093/cid/ciad428
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48
- (2023) Tomefa E Asempa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Trends of β-Lactamase Occurrence among Escherichia coli and Klebsiella pneumoniae in United States Hospitals during a 5-year period and Activity of Antimicrobial Agents against Isolates Stratified by β-Lactamase Type
- (2023) Mariana Castanheira et al. Open Forum Infectious Diseases
- Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
- (2023) Jinnethe Reyes et al. Lancet Microbe
- In vitro Time Kill of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli using Cation Adjusted Muller Hinton Broth and ISO-Sensitest Broth
- (2022) Maxwell J. Lasko et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol for the Treatment of Infections Due To Metallo-Beta-Lactamase-Producing Pathogens in the CREDIBLE-CR And APEKS-NP Phase 3 Randomized Studies
- (2022) Jean-Francois Timsit et al. CLINICAL INFECTIOUS DISEASES
- Evolution of imipenem-relebactam resistance following treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia
- (2022) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology of extended-spectrum β-lactamase–producing Enterobacterales in five US sites participating in the Emerging Infections Program, 2017
- (2022) Nadezhda Duffy et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
- (2022) Christopher JL Murray et al. LANCET
- Ceftolozane-tazobactam versus colistin for the treatment of infections due to drug-resistant Pseudomonas aeruginosa. A multicenter cohort study
- (2022) Thamer A Almangour et al. Journal of Global Antimicrobial Resistance
- Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals
- (2022) Sadia H Sarzynski et al. Open Forum Infectious Diseases
- Efficacy of Eravacycline Versus Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) Acinetobacter baumannii
- (2022) Courtney J. Scott et al. ANNALS OF PHARMACOTHERAPY
- Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam
- (2022) T. A. Alsenani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
- (2022) Marco Falcone et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020
- (2022) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Increased bla KPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate
- (2022) Paolo Gaibani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Class C β-Lactamases: Molecular Characteristics
- (2022) Alain Philippon et al. CLINICAL MICROBIOLOGY REVIEWS
- Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales
- (2022) Mark Biagi et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review
- (2022) Andrew Chou et al. DRUGS
- Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
- (2022) V Adámková et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments
- (2022) Paolo Gaibani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In-vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance
- (2022) Jacqueline Findlay et al. Journal of Global Antimicrobial Resistance
- Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection
- (2022) Juan Chen et al. Infection and Drug Resistance
- The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections
- (2022) Aisling R. Caffrey et al. Antibiotics-Basel
- Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
- (2022) Paolo Gaibani et al. Antibiotics-Basel
- Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review
- (2022) Alessandra Belati et al. Antibiotics-Basel
- Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
- (2022) Stamatis Karakonstantis et al. Antibiotics-Basel
- NDM-35-Producing ST167 Escherichia coli Highly Resistant to β-Lactams Including Cefiderocol
- (2022) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline
- (2022) Sara E. Boyd et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of resistance to newer antimicrobials among carbapenem-resistant Klebsiella pneumoniae in the post–acute-care setting
- (2022) Helen L. Zhang et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates
- (2022) Pranita D. Tamma et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era
- (2022) Priya Sreenivasan et al. JOURNAL OF ANTIBIOTICS
- Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial
- (2022) David L Paterson et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evolution of β-lactamase-mediated cefiderocol resistance
- (2022) Christopher Fröhlich et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Community-acquired bacteremia by Klebsiella pneumoniae producing KPC-3 and resistant to ceftazidime/avibactam
- (2022) I Machuca et al. Journal of Global Antimicrobial Resistance
- In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
- (2022) James A. Karlowsky et al. Microbiology Spectrum
- Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy
- (2022) Emanuela Zappulo et al. ANNALS OF HEMATOLOGY
- In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii - calcoaceticus Complex Collected from 2016 to 2021
- (2022) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials
- (2022) Christopher Longshaw et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
- (2022) Abiu Sempere et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits
- (2022) Vidmantas Petraitis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales
- (2022) Pranita D Tamma et al. CLINICAL INFECTIOUS DISEASES
- Trimethoprim/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model
- (2022) Maxwell J Lasko et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study
- (2022) Paul Chabert et al. Annals of Intensive Care
- Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient
- (2022) Paolo Gaibani et al. Journal of Global Antimicrobial Resistance
- Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study
- (2022) Hakeam A. Hakeam et al. Journal of Infection and Public Health
- Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
- (2022) Sara Alosaimy et al. Microbiology Spectrum
- Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
- (2022) Stefano Stracquadanio et al. Microbiology Spectrum
- Fosfomycin Pharmacokinetic Profile in Plasma and Urine and Quantitative Estimation in Prostate and Seminal Vesicles after One and Two Consecutive Doses of Oral Fosfomycin Trometamol in Healthy Male Volunteers
- (2022) Andrea F. D. Di Stefano et al. Antibiotics-Basel
- Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections
- (2022) Dana J. Holger et al. Infectious Diseases and Therapy
- Clinical outcome of wild-type AmpC-producing Enterobacterales infection in critically ill patients treated with β-lactams: a prospective multicenter study
- (2022) Roman Mounier et al. Annals of Intensive Care
- Synergistic rifabutin and colistin reduce emergence of resistance when treating Acinetobacter baumannii
- (2021) Jiaqi Cheng et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic
- (2021) Ana Paula Streling et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Activity and In Vivo Efficacy of Cefiderocol Against Stenotrophomonas maltophilia
- (2021) Rio Nakamura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro
- (2021) Qiuxia Lin et al. BMC MICROBIOLOGY
- Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
- (2021) James A. Karlowsky et al. BMC MICROBIOLOGY
- Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study
- (2021) Mario Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam
- (2021) Abigail M. Rubio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019
- (2021) Andrew Walkty et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Activity of Imipenem/Relebactam and Comparators Against Gram-Negative Pathogens from Patients with Bloodstream Infections in the United States and Canada – SMART 2018-2019
- (2021) Sibylle H. Lob et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan
- (2021) Shu-Chen Kuo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Prevalence of blaCTX-M Genes in Gram-Negative Bloodstream Isolates across 66 Hospitals in the United States
- (2021) Pranita D. Tamma et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial
- (2021) Adam G. Stewart et al. Trials
- Amikacin nebulization for the adjunctive therapy of gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials
- (2021) Jun-Ping Qin et al. Scientific Reports
- Evaluation of susceptibility testing methods for aztreonam (ATM) and ceftazidime/avibactam (CZA) combination therapy on extensively drug-resistant Gram-negative organisms
- (2021) Ayesha Khan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Imipenem-Relebactam Susceptibility and Genotypic Characteristics of Carbapenem-Resistant Enterobacterales (CRE) Identified during Population-Based Surveillance
- (2021) Sam Horwich-Scholefield et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New Perspectives on Antimicrobial Agents: Cefiderocol
- (2021) Erin K. McCreary et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- StenoSCORE: Predicting Stenotrophomonas maltophilia Bloodstream Infections in the Hematologic Malignancy Population
- (2021) Sara M. Karaba et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa : Implications for Dose Optimization
- (2021) Christian M. Gill et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
- (2021) Christian M. Gill et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration
- (2021) Andrew J. Fratoni et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis
- (2021) Alessandra Mularoni et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Effectiveness of ceftazidime–avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia
- (2021) Hakeam A. Hakeam et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision
- (2021) Andrew J Fratoni et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates
- (2021) Mariana Castanheira et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia
- (2021) Ayesha Khan et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Treatment of Patients with Serious Infections Due to Carbapenem‐resistant Acinetobacter baumannii : How Viable are the Current Options?
- (2021) J Nicholas O’Donnell et al. PHARMACOTHERAPY
- Susceptibility to Imipenem/Relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii Isolates from Chinese Intra-Abdominal, Respiratory and Urinary Tract Infections: SMART 2015 to 2018
- (2021) Hui Zhang et al. Infection and Drug Resistance
- Risk Factors of Death in Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacterales in Patients with Neoplasia
- (2021) Tiago da Cunha Ferreira et al. Infection and Drug Resistance
- Ceftolozane/tazobactam and imipenem/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards – SMART United States 2017-2019
- (2021) Sibylle H Lob et al. Open Forum Infectious Diseases
- Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)
- (2021) Adam G Stewart et al. Open Forum Infectious Diseases
- Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
- (2021) Sara Alosaimy et al. Open Forum Infectious Diseases
- Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
- (2021) Patricia J Simner et al. Open Forum Infectious Diseases
- In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial
- (2021) Adam G. Stewart et al. Microbiology Spectrum
- In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii
- (2021) Jacinda C. Abdul-Mutakabbir et al. Antibiotics-Basel
- The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
- (2021) Carola Mauri et al. Antibiotics-Basel
- Tigecycline in the Treatment of Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia: A Multicenter Retrospective Cohort Study
- (2021) Lei Zha et al. Infectious Diseases and Therapy
- Detection and Characterization of Targeted Carbapenem-Resistant Health Care-Associated Threats: Findings from the Antibiotic Resistance Laboratory Network, 2017 to 2019
- (2021) Sarah Sabour et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
- (2021) Thijs ten Doesschate et al. CLINICAL INFECTIOUS DISEASES
- Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression
- (2021) Patricia J Simner et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology and in vitro activity of ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates
- (2021) Sofia Maraki et al. INFECTION
- Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones
- (2021) María A. Gomis-Font et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia
- (2021) Ignacio Martin-Loeches et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluating Metabolic Pathways and Biofilm Formation in Stenotrophomonas maltophilia
- (2021) Cierra M. Isom et al. JOURNAL OF BACTERIOLOGY
- Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019
- (2021) Michael A. Pfaller et al. Journal of Global Antimicrobial Resistance
- A Retrospective Case Series of Concomitant Carbapenem and Valproic Acid Use: Are Best Practice Advisories Working?
- (2021) Andrew J. Fratoni et al. JOURNAL OF PHARMACY PRACTICE
- Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
- (2020) Lei Zha et al. ADVANCES IN THERAPY
- Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016-2018
- (2020) Michael A. Pfaller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017
- (2020) Sarah M. McLeod et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
- (2020) Kenneth V.I. Rolston et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
- (2020) Renee Ackley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Epidemiology of β-Lactamase-Producing Pathogens
- (2020) Karen Bush et al. CLINICAL MICROBIOLOGY REVIEWS
- In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units
- (2020) Alyssa R. Golden et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- In vitro efficacy of Imipenem-Relebactam and Cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae
- (2020) L. Tselepis et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam/avibactam
- (2020) Hariharan Periasamy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017
- (2020) Sibylle H. Lob et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
- (2020) David van Duin et al. LANCET INFECTIOUS DISEASES
- Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
- (2020) Ahmed M Hamdi et al. Open Forum Infectious Diseases
- Early Experience with Eravacycline for Complicated Infections
- (2020) S Alosaimy et al. Open Forum Infectious Diseases
- Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections
- (2020) Sara Alosaimy et al. Open Forum Infectious Diseases
- Structural basis of reduced susceptibility to ceftazidime–avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion
- (2020) Akito Kawai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016–2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides
- (2020) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime
- (2020) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-Avibactam Activity against a Challenge Set of Carbapenem-Resistant Enterobacterales: Ompk36 L3 Alterations and β-Lactamases with Ceftazidime Hydrolytic Activity Lead to Elevated MIC Values
- (2020) Mariana Castanheira et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study
- (2020) Tommaso Cai et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model
- (2020) Thomas P Lodise et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012–2017
- (2020) John A. Jernigan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia
- (2020) Matthias I. Gröschel et al. Nature Communications
- Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
- (2020) Matteo Bassetti et al. Open Forum Infectious Diseases
- The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study
- (2020) Bin Cai et al. Open Forum Infectious Diseases
- Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline
- (2020) Sara E Boyd et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018
- (2020) Dong Dong et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Fosfomycin for Bacterial Prostatitis: A Review
- (2020) Alex C. Kwan et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
- (2020) Harald Seifert et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of Omadacycline and Other Tetracyclines Against Contemporary Gram-Negative Pathogens from New York City Hospitals
- (2020) Alejandro Iregui et al. Microbial Drug Resistance
- Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016–2018
- (2020) Helio S. Sader et al. Microbial Drug Resistance
- Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
- (2020) Gennaro De Pascale et al. Annals of Intensive Care
- Phenotypic synergy testing of ceftazidime–avibactam with aztreonam in a university hospital having high number of metallobetalactamase producing bacteria
- (2020) Chinmoy Sahu et al. Infectious Diseases
- A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii
- (2020) Brian Luna et al. Nature Microbiology
- Multicenter, Observational Cohort Study Evaluating Third-Generation Cephalosporin Therapy for Bloodstream Infections Secondary to Enterobacter, Serratia, and Citrobacter Species
- (2020) Caroline Derrick et al. Antibiotics-Basel
- In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant gram-negative bacteria
- (2020) Shazad Mushtaq et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide
- (2020) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations
- (2020) Krisztina M. Papp-Wallace et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis—authors’ response
- (2020) Meital Elbaz et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms
- (2020) Vincent Trebosc et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-negative Bacilli: A Comparison of Disk Diffusion to Broth Microdilution
- (2020) C. Paul Morris et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Cefiderocol: the Trojan horse has arrived but will Troy fall?
- (2020) Emily L Heil et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- Treatment of Bacteremia Caused by Enterobacter spp.: Should the Potential for AmpC Induction Dictate Therapy? A Retrospective Study
- (2020) Genady Drozdinsky et al. Microbial Drug Resistance
- Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis
- (2020) Jiating Liu et al. Journal of Global Antimicrobial Resistance
- Pharmacology, Dosing, and Side Effects of Rifabutin as a Possible Therapy for Antibiotic-Resistant Acinetobacter Infections
- (2020) M C Phillips et al. Open Forum Infectious Diseases
- Minocycline alone and in combination with polymyxin B, meropenem, and sulbactam against carbapenem- susceptible and resistant Acinetobacter baumannii in in vitro pharmacodynamic model
- (2020) Maya Beganovic et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
- (2020) Nao Kawaguchi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of aztreonam in combination with ceftazidime–avibactam against serine- and metallo-β-lactamase–producing Pseudomonas aeruginosa
- (2020) Michelle Lee et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients
- (2020) Marco Falcone et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study
- (2020) I Karaiskos et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii
- (2020) A R Noel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales
- (2020) Amelia Bhatnagar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Optimization of Aztreonam in Combination with Ceftazidime/Avibactam in a Cystic Fibrosis Patient with Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring
- (2020) Mallory C. Cowart et al. THERAPEUTIC DRUG MONITORING
- A mouse model of rapidly progressive fatal haemorrhagic pneumonia caused by Stenotrophomonas maltophilia
- (2020) Waki Imoto et al. Journal of Global Antimicrobial Resistance
- Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae
- (2019) William R. Wilson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
- (2019) Christopher Fröhlich et al. mSphere
- Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
- (2019) Tianshui Niu et al. Antimicrobial Resistance and Infection Control
- Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia
- (2019) Pranita D. Tamma et al. JAMA Internal Medicine
- Once-Daily Plazomicin for Complicated Urinary Tract Infections
- (2019) Florian M.E. Wagenlehner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interplay between β-lactamases and new β-lactamase inhibitors
- (2019) Karen Bush et al. NATURE REVIEWS MICROBIOLOGY
- Oral fosfomycin for the treatment of chronic bacterial prostatitis
- (2019) Ilias Karaiskos et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2
- (2019) Peera Hemarajata et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients
- (2019) Roxana Zamudio et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016
- (2019) Irene Galani et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Association between Antibiotic Use and Hospital-Onset Clostridioides difficile Infection in U.S. Acute Care Hospitals, 2006-2012: an Ecologic Analysis
- (2019) Sophia V Kazakova et al. CLINICAL INFECTIOUS DISEASES
- A Primer on AmpC Beta-Lactamases: Necessary Knowledge for an Increasingly Multidrug-Resistant World
- (2019) Pranita D Tamma et al. CLINICAL INFECTIOUS DISEASES
- Characterization of β-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed Phase 3 trial (REPRISE) for ceftazidime-avibactam: Correlation of efficacy against β-lactamase producers
- (2019) Rodrigo E. Mendes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Aztreonam plus clavulanate, tazobactam or avibactam for the treatment of metallo-β-lactamase-producing-Gram negative related infections
- (2019) Cécile Emeraud et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent β-lactam-β-lactamase inhibitor combination
- (2019) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparison of ceftazidime-avibactam and Ceftolozane-Tazobactam in vitro activities when tested against gram-negative Bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018)
- (2019) Helio S. Sader et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- IMI/REL versus P. aeruginosa from US SMART 2015–2017
- (2019) James A. Karlowsky et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018
- (2019) Kati Räisänen et al. Eurosurveillance
- Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia
- (2019) Megan D Shah et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015–17
- (2019) Sibylle H Lob et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Substantial Contribution of SmeDEF, SmeVWX, SmQnr, and Heat Shock Response to Fluoroquinolone Resistance in Clinical Isolates of Stenotrophomonas maltophilia
- (2019) Chao-Jung Wu et al. Frontiers in Microbiology
- Characterization of Phenotypic and Genotypic Diversity of Stenotrophomonas maltophilia Strains Isolated From Selected Hospitals in Iran
- (2019) Narjess Bostanghadiri et al. Frontiers in Microbiology
- Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis
- (2019) Matthew P Cheng et al. Open Forum Infectious Diseases
- Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae
- (2019) Matthew C. Canver et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models
- (2019) Rio Nakamura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China
- (2019) Chunjiang Zhao et al. BMC INFECTIOUS DISEASES
- Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy
- (2019) Andreas F. Widmer et al. INFECTION
- Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo
- (2019) Stephan Göttig et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates
- (2019) Zachary S. Elliott et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Induction of plasmid-mediated AmpC β-lactamase DHA-1 by piperacillin/tazobactam and other β-lactams in Enterobacteriaceae
- (2019) Kentaro Akata et al. PLoS One
- Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States
- (2019) Maria F. Mojica et al. mBio
- Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in blaKPC-3-harboring Klebsiella pneumoniae
- (2019) Carolina Venditti et al. Infection and Drug Resistance
- In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program (2014-2018)
- (2019) Robert K. Flamm et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia infections
- (2019) Cara Nys et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam
- (2019) M Biagi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
- (2019) Basem M. Alraddadi et al. BMC INFECTIOUS DISEASES
- Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa
- (2019) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China
- (2019) P. Zhang et al. CLINICAL MICROBIOLOGY AND INFECTION
- Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase–producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis
- (2019) O. Senard et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical
- (2019) Luisa Sorlí et al. JOURNAL OF INFECTION
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- Dynamic Emergence of Mismatch Repair Deficiency Facilitates Rapid Evolution of Ceftazidime-Avibactam Resistance in Pseudomonas aeruginosa Acute Infection
- (2019) Pavel P. Khil et al. mBio
- Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016
- (2019) Tingting Xiao et al. Antimicrobial Resistance and Infection Control
- Molecular Epidemiology of Ceftriaxone-Nonsusceptible Enterobacterales Isolates in an Academic Medical Center in the United States
- (2019) Pranita D Tamma et al. Open Forum Infectious Diseases
- Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs ß-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis
- (2019) Chitra Punjabi et al. Open Forum Infectious Diseases
- Characterization of carbapenem-resistant but cephalosporin-susceptible Pseudomonas aeruginosa
- (2019) Younes Khalili et al. ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA
- A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment
- (2019) Thibaud Boulant et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model
- (2019) Iris H. Chen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals During 2016-2018
- (2019) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam resistant mutants
- (2019) Pablo Fraile-Ribot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Charting the Path Forward Development, Goals and Initiatives of the 2019 IDSA Strategic Plan
- (2019) Cynthia L Sears et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
- (2019) Yoshinori Yamano CLINICAL INFECTIOUS DISEASES
- Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization
- (2019) P. Gaibani et al. CLINICAL MICROBIOLOGY AND INFECTION
- Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics
- (2019) Keith A. Rodvold et al. CLINICAL PHARMACOKINETICS
- In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART Surveillance United States 2015–2017
- (2019) James A. Karlowsky et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases
- (2019) Laura Benchetrit et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015–17)
- (2019) Iris Spiliopoulou et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of potential alternative treatment agents for Stenotrophomonas maltophilia non-susceptible to levofloxacin and/or trimethoprim/sulfamethoxazole
- (2019) M Biagi et al. JOURNAL OF CLINICAL MICROBIOLOGY
- In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia
- (2019) Nam Su Ku et al. Scientific Reports
- Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat
- (2019) David A. Butler et al. Current Infectious Disease Reports
- In vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance United States 2015-2017
- (2019) James A. Karlowsky et al. Journal of Global Antimicrobial Resistance
- Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: report of a case and review of the literature
- (2019) Ángela Cano et al. Journal of Global Antimicrobial Resistance
- Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
- (2019) Olexiy Sagan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia
- (2019) David L. Paterson et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems
- (2019) Sock Hoon Tan et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam
- (2019) Elske Sieswerda et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial
- (2019) Michael S Niederman et al. LANCET INFECTIOUS DISEASES
- In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from United States Hospitals and Comparative Activity of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes
- (2018) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
- (2018) Michael A. Pfaller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
- (2018) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam
- (2018) Michiyoshi Nukaga et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different β-lactam resistance phenotypes
- (2018) Frédéric Robin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program
- (2018) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
- (2018) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae
- (2018) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae
- (2018) Mario Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii
- (2018) T. Amat et al. CLINICAL MICROBIOLOGY AND INFECTION
- Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii
- (2018) C.-A. Liang et al. CLINICAL MICROBIOLOGY AND INFECTION
- Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program
- (2018) Dee Shortridge et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase–producing Enterobacteriaceae in an Italian Internal Medicine ward
- (2018) Simone Meini et al. European Journal of Internal Medicine
- Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae
- (2018) Se Ah Kim et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme
- (2018) Michael A. Pfaller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii
- (2018) Harald Seifert et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013–2015)
- (2018) M.A. Pfaller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection
- (2018) Keith S. Kaye et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women
- (2018) Angela Huttner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase
- (2018) Rebekka Kohlmann et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa
- (2018) Helio S Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme
- (2018) James A Karlowsky et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
- (2018) Gregory G Stone et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Risk factors for death from Stenotrophomonas maltophilia bacteremia
- (2018) Kayo Osawa et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
- (2018) Mical Paul et al. LANCET INFECTIOUS DISEASES
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013–2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility
- (2018) Dee Shortridge et al. Microbial Drug Resistance
- Effect of Porins and blaKPC Expression on Activity of Imipenem with Relebactam in Klebsiella pneumoniae: Can Antibiotic Combinations Overcome Resistance?
- (2018) Gregory Balabanian et al. Microbial Drug Resistance
- Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections
- (2018) Lucas Watson et al. Journal of Global Antimicrobial Resistance
- Activity of Imipenem-Relebactam against Gram-Negative Bacilli from Global ICU and Non-ICU Wards — SMART 2015-2016
- (2018) Sibylle H. Lob et al. Journal of Global Antimicrobial Resistance
- Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program
- (2018) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands
- (2018) Manuel Díaz-Cañestro et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Assessing the In Vitro Activity of Ceftazidime/Avibactam and Aztreonam Among Carbapenemase-Producing Enterobacteriaceae: Defining the Zone of Hope
- (2018) Lindsay M. Avery et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17)
- (2018) Helio S Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates
- (2018) Pranita D. Tamma et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates
- (2018) Shio-Shin Jean et al. MEDICINE
- Meropenem/colistin versus meropenem/ampicillin–sulbactam in the treatment of carbapenem-resistant pneumonia
- (2018) Hossein Khalili et al. Journal of Comparative Effectiveness Research
- Activity of Imipenem-Relebactam against Pseudomonas aeruginosa with Antimicrobial-Resistant Phenotypes from Seven Global Regions—SMART 2015-2016
- (2018) James A. Karlowsky et al. Journal of Global Antimicrobial Resistance
- Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam
- (2018) Stan Atkin et al. Infection and Drug Resistance
- Carbapenem-resistant and cephalosporin-susceptible Pseudomonas aeruginosa: a notable phenotype in patients with bacteremia
- (2018) Shuang Li et al. Infection and Drug Resistance
- Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals
- (2018) Menglan Zhou et al. Infection and Drug Resistance
- Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying blaKPC-2 Reveals a Heterogenous Population and Reversible Genotype
- (2018) Mariana Castanheira et al. mSphere
- Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem
- (2018) David C. Griffith et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient
- (2018) Vasilios Athans et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
- (2018) Michael R. Jacobs et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful treatment of a bacteremia due to NDM-1-producing Morganella morganii with Aztreonam and Ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy
- (2018) Claire Amaris Hobson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treatment outcomes of colistin and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial
- (2018) Yaakov Dickstein et al. CLINICAL INFECTIOUS DISEASES
- IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections
- (2018) Joseph S Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis
- (2018) J.-H. Ko et al. CLINICAL MICROBIOLOGY AND INFECTION
- Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers
- (2018) Cecilia G. Carvalhaes et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016
- (2018) Fiona Senchyna et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Pathogenic significance of hemorrhagic pneumonia in hematologic malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and microbiological analysis
- (2018) Si-Ho Kim et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- CLINICAL CHARACTERISTICS AND PROGNOSIS OF INFECTIONS CAUSED BY OXA-48 CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE IN PATIENTS TREATED WITH CEFTAZIDIME-AVIBACTAM
- (2018) C. De la Calle et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
- (2018) James A. Karlowsky et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
- (2018) Krystyna M. Kazmierczak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan
- (2018) Shun-Chung Hsueh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing
- (2018) Sònia Martínez-Servat et al. Frontiers in Microbiology
- Colistin Monotherapy Versus Colistin and Rifampin Combination Therapy in Pneumonia Caused by Colistin-resistant Acinetobacter baumannii: A Randomized Controlled Trial
- (2018) Hye Jung Park et al. Journal of Global Antimicrobial Resistance
- 696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
- (2018) Akinobu Ito et al. Open Forum Infectious Diseases
- The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection
- (2018) Soichi Arakawa et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
- (2017) J. Dobias et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study
- (2017) J.-H. Ko et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli
- (2017) Young Kyung Yoon et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients
- (2017) Juan J. Castón et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia : in vitro effects and clinical efficacy in cancer patients
- (2017) Hideki Araoka et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
- (2017) Diego Maselli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial
- (2017) Hong Ren et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
- (2017) Matthew Sims et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Reporting antimicrobial susceptibilities and resistance phenotypes in Acinetobacter spp: a nationwide proficiency study
- (2017) Felipe Fernández-Cuenca et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
- (2017) Matthew E. Falagas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection
- (2017) Evelyn Shaw et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)
- (2017) Michael A. Pfaller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models
- (2017) Cornelia B Landersdorfer et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
- (2017) Pablo A Fraile-Ribot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate
- (2017) Gina K. Thomson et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii
- (2017) Ji Young Jang et al. JOURNAL OF CRITICAL CARE
- Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene
- (2017) Ryota Ito et al. mBio
- Association of Adverse Events With Antibiotic Use in Hospitalized Patients
- (2017) Pranita D. Tamma et al. JAMA Internal Medicine
- Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial
- (2017) Joseph Solomkin et al. JAMA Surgery
- Ceftolozane–tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013–2015)
- (2017) M.A. Pfaller et al. Journal of Global Antimicrobial Resistance
- Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii
- (2017) Yong Kyun Kim et al. Journal of Thoracic Disease
- Minocycline in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae
- (2017) Akshay Khatri et al. Open Forum Infectious Diseases
- Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
- (2016) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014
- (2016) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii
- (2016) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae
- (2016) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014
- (2016) Michael D. Huband et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
- (2016) Belén Gutiérrez-Gutiérrez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B
- (2016) Maria Helena Rigatto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
- (2016) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient
- (2016) Maria F. Mojica et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoandIn VitroEfficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii
- (2016) Ya-Sung Yang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014
- (2016) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)
- (2016) Boudewijn L. M. de Jonge et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
- (2016) Takahiko Fukuchi et al. BMC INFECTIOUS DISEASES
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production inEnterobacteriaceaeBloodstream Infections at a Major Cancer Center: Table 1.
- (2016) Samuel L. Aitken et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
- (2016) Andre C. Kalil et al. CLINICAL INFECTIOUS DISEASES
- Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia
- (2016) M.P. Freire et al. CLINICAL MICROBIOLOGY AND INFECTION
- Inhaled Antibiotics for Gram-Negative Respiratory Infections
- (2016) Eric Wenzler et al. CLINICAL MICROBIOLOGY REVIEWS
- The Role of Aerolized Colistin in the Treatment of Hospital-Acquired Pneumonia
- (2016) Pervin Korkmaz Ekren et al. CRITICAL CARE MEDICINE
- Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia , and Burkholderia cepacia species complex isolates from a global surveillance program (2013)
- (2016) Robert K. Flamm et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- The epidemiology of carbapenemases in Latin America and the Caribbean
- (2016) Kevin Escandón-Vargas et al. Expert Review of Anti-Infective Therapy
- Synergistic combinations of polymyxins
- (2016) Justin R. Lenhard et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections
- (2016) Shauna Jacobson et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment ofStenotrophomonas maltophiliainfections
- (2016) Elizabeth Hand et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials
- (2016) Myra W. Popejoy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method
- (2016) Kenneth P. Smith et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization
- (2016) Tai-Chin Hsieh et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia
- (2016) Yong Duk Jeon et al. MEDICINE
- Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections
- (2016) Wentao Ni et al. MEDICINE
- Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam
- (2016) Murat DİZBAY et al. Turkish Journal Of Medical Sciences
- Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012–2014
- (2016) Helio S. Sader et al. Surgical Infections
- Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?
- (2016) Tuna Demirdal et al. Annals of Clinical Microbiology and Antimicrobials
- In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates
- (2016) Christina A. Sutherland et al. Annals of Clinical Microbiology and Antimicrobials
- Rifamycins, Alone and in Combination
- (2016) David M. Rothstein Cold Spring Harbor Perspectives in Medicine
- Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial
- (2016) Sami Abdellatif et al. Annals of Intensive Care
- Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-ProducingEnterobacteriaceaeBacteremia: Table 1.
- (2016) Ruibin Wang et al. Open Forum Infectious Diseases
- Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies
- (2016) Antoine Grillon et al. PLoS One
- Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
- (2016) Tat Ming Ng et al. PLoS One
- The Efflux Pump SmeDEF Contributes to Trimethoprim-Sulfamethoxazole Resistance in Stenotrophomonas maltophilia
- (2015) María Blanca Sánchez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
- (2015) William F. Penwell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates
- (2015) Nan-Yao Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Assessment of Minocycline and Polymyxin B Combination against Acinetobacter baumannii
- (2015) Dana R. Bowers et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
- (2015) M. Berrazeg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
- (2015) Romney M. Humphries et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013
- (2015) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia
- (2015) Yasufumi Matsumura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
- (2015) Krystyna M. Kazmierczak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
- (2015) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations
- (2015) Sung-Yeon Cho et al. BMC INFECTIOUS DISEASES
- Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs: Figure 1.
- (2015) M. Lindsay Grayson et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
- (2015) Joseph Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
- (2015) Zubair A. Qureshi et al. CLINICAL INFECTIOUS DISEASES
- High-level quinolone resistance is associated with the overexpression of smeVWX in Stenotrophomonas maltophilia clinical isolates
- (2015) G. García-León et al. CLINICAL MICROBIOLOGY AND INFECTION
- Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study
- (2015) O. Zusman et al. CLINICAL MICROBIOLOGY AND INFECTION
- Genetic Variability of AdeRS Two-Component System Associated with Tigecycline Resistance in XDR-Acinetobacter baumannii Isolates
- (2015) S. Montaña et al. CURRENT MICROBIOLOGY
- Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011–2014)
- (2015) Helio S. Sader et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae
- (2015) Hadas Ofer-Friedman et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study
- (2015) Chen-Hsiang Lee et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study
- (2015) Marta Tato et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia
- (2015) Helio S. Sader et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
- (2015) Akinobu Ito et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
- (2015) S. D. Lahiri et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused byEnterobacter,CitrobacterorSerratiaspecies: a systematic review with meta-analysis
- (2015) Patrick N. A. Harris et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of ceftazidime/avibactam against isogenic strains ofEscherichia colicontaining KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop
- (2015) Marisa L. Winkler et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia
- (2015) Gul R. Yilmaz et al. Journal of Infection in Developing Countries
- Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
- (2015) Ya-Ting Chang et al. Frontiers in Microbiology
- Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae
- (2015) Patrick N A Harris et al. Antimicrobial Resistance and Infection Control
- A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused byStenotrophomonas maltophilia
- (2015) Chuanqi Wei et al. Infectious Diseases
- Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients
- (2014) Matthieu Boisson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals
- (2014) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy
- (2014) K. Phe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
- (2014) Rujipas Sirijatuphat et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City
- (2014) Marie Abdallah et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
- (2014) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
- (2014) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012
- (2014) A. Walkty et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems
- (2014) George L. Daikos et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical and microbiological characteristics of bloodstream infections due to AmpC β-lactamase producing Enterobacteriaceae: an active surveillance cohort in a large centralized Canadian region
- (2014) Vikas P Chaubey et al. BMC INFECTIOUS DISEASES
- Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia
- (2014) M. J. Siedner et al. CLINICAL INFECTIOUS DISEASES
- Update on Acinetobacter Species: Mechanisms of Antimicrobial Resistance and Contemporary In Vitro Activity of Minocycline and Other Treatment Options
- (2014) Mariana Castanheira et al. CLINICAL INFECTIOUS DISEASES
- Bad Bugs Need Old Drugs: A Stewardship Program's Evaluation of Minocycline for Multidrug-Resistant Acinetobacter baumannii Infections
- (2014) Debra A. Goff et al. CLINICAL INFECTIOUS DISEASES
- A Review of Intravenous Minocycline for Treatment of Multidrug-Resistant Acinetobacter Infections
- (2014) David J. Ritchie et al. CLINICAL INFECTIOUS DISEASES
- Carbapenem-Resistance in Gram-Negative Bacilli and Intravenous Minocycline: An Antimicrobial Stewardship Approach at the Detroit Medical Center
- (2014) Jason M. Pogue et al. CLINICAL INFECTIOUS DISEASES
- In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae
- (2014) Y. Harada et al. CLINICAL MICROBIOLOGY AND INFECTION
- Serum Peak Sulfamethoxazole Concentrations Demonstrate Difficulty in Achieving a Target Range: A Retrospective Cohort Study
- (2014) Bao D. Dao et al. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
- Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase–producing Proteus mirabilis
- (2014) Hsih-Yeh Tsai et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
- (2014) A. Batirel et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae
- (2014) B. Pilmis et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections
- (2014) Matthew E. Falagas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort
- (2014) L. E. Lopez-Cortes et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Unbound fraction of ertapenem in intensive care unit patients
- (2014) Uwe Liebchen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Is Tigecycline a Good Choice in the Treatment of Multidrug-ResistantAcinetobacter baumanniiPneumonia?
- (2014) MS Tasbakan et al. JOURNAL OF CHEMOTHERAPY
- Clinical spectrum of urine cultures positive for ESBL-producing Escherichia coli in hospitalized patients and impact on antibiotic use
- (2014) R. Lepeule et al. MEDECINE ET MALADIES INFECTIEUSES
- Clinical Factors Associated with Acquisition of Resistance to Levofloxacin inStenotrophomonas maltophilia
- (2014) Ji Hyeon Baek et al. YONSEI MEDICAL JOURNAL
- Influencing factors of successful eradication of multidrug-resistant Acinetobacter baumannii in the respiratory tract with aerosolized colistin
- (2014) Chin-Chou Wang et al. Biomedical Journal
- Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection
- (2013) Kevin A. Brown et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Systematic Review and Meta-Analysis ofIn VitroSynergy of Polymyxins and Carbapenems
- (2013) Oren Zusman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin Resistance in a Clinical Acinetobacter baumannii Strain Appearing after Colistin Treatment: Effect on Virulence and Bacterial Fitness
- (2013) Rafael López-Rojas et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam
- (2013) Sutep Jaruratanasirikul et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Monotherapy with Fluoroquinolone or Trimethoprim-Sulfamethoxazole for Treatment of Stenotrophomonas maltophilia Infections
- (2013) Yu Lin Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Can Levofloxacin Be a Useful Alternative to Trimethoprim-Sulfamethoxazole for Treating Stenotrophomonas maltophilia Bacteremia?
- (2013) Sun Young Cho et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups
- (2013) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012
- (2013) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria
- (2013) Nicola Petrosillo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Aerosolized Colistin as Adjunctive Treatment on the Outcomes of Microbiologically Documented Ventilator-Associated Pneumonia Caused by Colistin-Only Susceptible Gram-Negative Bacteria
- (2013) Mario Tumbarello et al. CHEST
- Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
- (2013) Emanuele Durante-Mangoni et al. CLINICAL INFECTIOUS DISEASES
- Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens
- (2013) Ana M. Sandri et al. CLINICAL INFECTIOUS DISEASES
- The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae
- (2013) Pranita D. Tamma et al. CLINICAL INFECTIOUS DISEASES
- Is Fosfomycin a Potential Treatment Alternative for Multidrug-Resistant Gram-Negative Prostatitis?
- (2013) B. J. Gardiner et al. CLINICAL INFECTIOUS DISEASES
- Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center
- (2013) Darowan S. Akajagbor et al. CLINICAL INFECTIOUS DISEASES
- Mechanisms of carbapenem resistance in cephalosporin-susceptible Pseudomonas aeruginosa in China
- (2013) Zhang-Rui Zeng et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia
- (2013) G. Kalin et al. INFECTION
- Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?
- (2013) Markus Hilty et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium
- (2013) Felipe F. Tuon et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies
- (2013) C. Eckmann et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- TEM-1 -lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii
- (2013) L. Krizova et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Emergence of Colistin-Resistance in Extremely Drug-Resistant Acinetobacter baumannii Containing a Novel pmrCAB Operon During Colistin Therapy of Wound Infections
- (2013) Emil Lesho et al. JOURNAL OF INFECTIOUS DISEASES
- Colistin inhalation monotherapy for ventilator-associated pneumonia ofAcinetobacter baumanniiin prematurity
- (2013) Chia-Hao Kang et al. PEDIATRIC PULMONOLOGY
- Inhaled Colistin for Treatment of Pneumonia due to Colistin-Only-SusceptibleAcinetobacter baumannii
- (2013) Hee Kyoung Choi et al. YONSEI MEDICAL JOURNAL
- Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study
- (2013) Neha M Doshi et al. BMC Anesthesiology
- Can ampicillin/sulbactam resistance in Acinetobacter baumannii be predicted accurately by disk diffusion?
- (2013) Giselle Fukita Viana et al. Journal of Global Antimicrobial Resistance
- Aerosolized Antibiotics for Ventilator-associated Pneumonia
- (2012) Jean-Jacques Rouby et al. ANESTHESIOLOGY
- Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii
- (2012) Qin Lu et al. ANESTHESIOLOGY
- Adverse Effects of Antimicrobials via Predictable or Idiosyncratic Inhibition of Host Mitochondrial Components
- (2012) Alison E. Barnhill et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
- (2012) Teena Chopra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hydrolysis Spectrum Extension of CMY-2-Like β-Lactamases Resulting from Structural Alteration in the Y-X-N Loop
- (2012) Sandrine Dahyot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniaein patients on maintenance hemodialysis
- (2012) Chih-Chao Yang et al. BMC INFECTIOUS DISEASES
- Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage
- (2012) K Tada et al. BONE MARROW TRANSPLANTATION
- Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae: MIC Matters
- (2012) Nan-Yao Lee et al. CLINICAL INFECTIOUS DISEASES
- Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
- (2012) P. D. Tamma et al. CLINICAL MICROBIOLOGY REVIEWS
- Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
- (2012) J. S. Brooke CLINICAL MICROBIOLOGY REVIEWS
- Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa
- (2012) Daniel J. Wolter et al. CURRENT PHARMACEUTICAL DESIGN
- Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia
- (2012) H. AYDEMIR et al. EPIDEMIOLOGY AND INFECTION
- Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy?
- (2012) H Gedik et al. Indian Journal of Medical Microbiology
- The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae
- (2012) Asako Doi et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Cefpodoxime vs Ciprofloxacin for Short-Course Treatment of Acute Uncomplicated Cystitis
- (2012) Thomas M. Hooton et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?
- (2012) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tigecycline as a therapeutic option inStenotrophomonas maltophiliainfections
- (2012) Yasemin Tezer Tekçe et al. JOURNAL OF CHEMOTHERAPY
- Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?
- (2012) Gamze Kalin et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial
- (2012) Torsten Sandberg et al. LANCET
- Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Infections among Solid Organ Transplant Recipients
- (2012) Ryan K. Shields et al. PLoS One
- Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy
- (2012) H. Araoka et al. Transplant Infectious Disease
- Efficacy of Tigecycline versus Ceftriaxone Plus Metronidazole for the Treatment of Complicated Intra-Abdominal Infections: Results from a Randomized, Controlled Trial
- (2012) Niels Qvist et al. Surgical Infections
- A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa
- (2011) Reinout Naesens et al. BMC INFECTIOUS DISEASES
- -Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
- (2011) J. Rodriguez-Bano et al. CLINICAL INFECTIOUS DISEASES
- International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
- (2011) Kalpana Gupta et al. CLINICAL INFECTIOUS DISEASES
- Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study
- (2011) S.-C. Kuo et al. CLINICAL MICROBIOLOGY AND INFECTION
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli or Klebsiella pneumoniae
- (2011) Nan-Yao Lee et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Efficacy and safety of tigecycline: a systematic review and meta-analysis
- (2011) Dafna Yahav et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli
- (2011) Philip M. Kurpiel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Detection of Favorable Oral Cephalosporin-Clavulanate Interactions by In Vitro Disk Approximation Susceptibility Testing of Extended-Spectrum-Beta-Lactamase-Producing Members of the Enterobacteriaceae
- (2011) J. D. Campbell et al. JOURNAL OF CLINICAL MICROBIOLOGY
- The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii
- (2011) Jung-Jr Ye et al. JOURNAL OF INFECTION
- The Outcomes of Using Colistin for Treating Multidrug Resistant Acinetobacter Species Bloodstream Infections
- (2011) Seung-Kwan Lim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality
- (2011) Alicia Hernández-Torres et al. MEDICINA CLINICA
- Trends in Antimicrobial Resistance of Acinetobacter baumannii Isolates from a Metropolitan Detroit Health System
- (2010) T. Reddy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Susceptibilities of a Worldwide Collection of Stenotrophomonas maltophilia Isolates Tested against Tigecycline and Agents Commonly Used for S. maltophilia Infections
- (2010) D. J. Farrell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Outbreak of Colistin-Resistant, Carbapenem-ResistantKlebsiella pneumoniaein Metropolitan Detroit, Michigan
- (2010) Dror Marchaim et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Aerosolized plus Intravenous Colistin versus Intravenous Colistin Alone for the Treatment of Ventilator‐Associated Pneumonia: A Matched Case‐Control Study
- (2010) Diamantis P. Kofteridis et al. CLINICAL INFECTIOUS DISEASES
- A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections
- (2010) S. Towfigh et al. CLINICAL MICROBIOLOGY AND INFECTION
- Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
- (2010) Antonio T. Freire et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009
- (2010) H. Araoka et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria
- (2010) P. Rattanaumpawan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia
- (2010) Samuel M. Moskowitz et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia
- (2010) N. C. Gordon et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Aerosolized Colistin for the Treatment of Multidrug-resistant Acinetobacter baumannii Pneumonia: Experience in a Tertiary Care Hospital in Northern Taiwan
- (2010) Cheng-Chih Lin et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Predictability of Doripenem Susceptibility inAcinetobacter baumanniiIsolates Based on Other Carbapenem Susceptibilities andblaOXAGene Status
- (2010) John S Esterly et al. PHARMACOTHERAPY
- Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia
- (2010) Jeannie D. Chan et al. JOURNAL OF INTENSIVE CARE MEDICINE
- Updated Functional Classification of -Lactamases
- (2009) K. Bush et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Enhancing Resistance to Cephalosporins in Class C β-Lactamases: Impact of Gly214Glu in CMY-2
- (2009) Andrea Endimiani et al. BIOCHEMISTRY
- Use of colistin in treating multi-resistant Gram-negative organisms in a specialised burns unit
- (2009) H. Ganapathy et al. BURNS
- Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study
- (2009) I.P. Korbila et al. CLINICAL MICROBIOLOGY AND INFECTION
- AmpC -Lactamases
- (2009) G. A. Jacoby CLINICAL MICROBIOLOGY REVIEWS
- Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
- (2009) P. D. Lister et al. CLINICAL MICROBIOLOGY REVIEWS
- Clinical Significance of the Pharmacokinetic and Pharmacodynamic Characteristics of Tigecycline
- (2009) Matthew Falagas et al. CURRENT DRUG METABOLISM
- Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity
- (2009) Maura S. Oliveira et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Fosfomycin in a single dose versus a 7-day course of amoxicillin–clavulanate for the treatment of asymptomatic bacteriuria during pregnancy
- (2009) A. Estebanez et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Attributable mortality ofStenotrophomonas maltophiliainfections: a systematic review of the literature
- (2009) Matthew E Falagas et al. Future Microbiology
- Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint
- (2009) Olaf Burkhardt et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients
- (2009) Matthew E. Falagas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs
- (2009) J. L. Crandon et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution
- (2009) Jason A. Roberts et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens
- (2009) Garyphallia Poulakou et al. JOURNAL OF INFECTION
- Stenotrophomonas maltophilia: an emerging opportunist human pathogen
- (2009) W John Looney et al. LANCET INFECTIOUS DISEASES
- Inhaled colistin as monotherapy for multidrug-resistant gram (−) nosocomial pneumonia: A case series
- (2009) Matthew E. Falagas et al. RESPIRATORY MEDICINE
- IRT and CMT β-lactamases and inhibitor resistance
- (2008) R. Cantón et al. CLINICAL MICROBIOLOGY AND INFECTION
- Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis
- (2008) A.J. Brink et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review
- (2008) Matthew E. Falagas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Unreliable Extended-Spectrum -Lactamase Detection in the Presence of Plasmid-Mediated AmpC in Escherichia coli Clinical Isolates
- (2008) F. J. L. Robberts et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review
- (2008) J.I. Garcia Paez et al. JOURNAL OF HOSPITAL INFECTION
- Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia
- (2008) Alex P. Betrosian et al. JOURNAL OF INFECTION
- Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: A prospective study
- (2008) Argyris Michalopoulos et al. RESPIRATORY MEDICINE
- Pseudomonas aeruginosa Susceptible Only to Colistin in Intensive Care Unit Patients
- (2008) Aikaterini Mastoraki et al. Surgical Infections
- The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants
- (2008) Lisa C Crossman et al. GENOME BIOLOGY
- Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure
- (2007) Kenji Murano et al. BIOORGANIC & MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now